GemPharmatech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	877.76	792.67	686.28	621.73	515.67	392.44
Other Revenue	0.37	0.72	0.56	0.45	0.87	1.34
Revenue	878.13	793.39	686.84	622.19	516.55	393.79
Revenue Growth	21.75%	15.51%	10.39%	20.45%	31.17%	50.35%
Cost of Revenue	315.89	288.94	261.33	202.86	150.22	101.27
Gross Profit	562.24	504.45	425.51	419.33	366.33	292.51
Selling, General & Admin	256.34	246.04	239.68	199.61	174.76	134.42
Research & Development	98.58	92.06	87.13	96.6	82.93	55.2
Other Operating Expenses	5.26	4.38	3.57	2.61	1.72	1.59
Operating Expenses	360.9	352.17	333.68	307.91	267.94	196.11
Operating Income	201.35	152.28	91.83	111.42	98.39	96.4
Interest Expense	-3.22	-6.08	-4.3	-2.76	-0.5	-0.74
Interest & Investment Income	21.47	19.31	22.39	28.65	23.73	14.43
Currency Exchange Gain (Loss)	-2.85	-0.91	1.69	0.08	1.49	-0.19
Other Non Operating Income (Expenses)	-9.6	-15.64	-21.56	-20.92	-11.32	-16.05
EBT Excluding Unusual Items	207.15	148.96	90.06	116.48	111.8	93.84
Gain (Loss) on Sale of Investments	1.25	0.69	2.34	2.73	-0.05	0.32
Gain (Loss) on Sale of Assets	-0.01	-0.04	0.01	-0.02	-0.1	0.05
Asset Writedown	-9.87	-	-	-	-	-
Other Unusual Items	13.24	15.3	26.8	42.1	62.03	49.1
Pretax Income	211.75	164.92	119.22	161.29	173.68	143.31
Income Tax Expense	29.2	22.29	9.4	2.37	9.02	18.39
Earnings From Continuing Operations	182.55	142.64	109.82	158.91	164.67	124.93
Net Income	182.55	142.64	109.82	158.91	164.67	124.93
Net Income to Common	182.55	142.64	109.82	158.91	164.67	124.93
Net Income Growth	74.87%	29.88%	-30.89%	-3.49%	31.81%	63.45%
Shares Outstanding (Basic)	404	408	407	407	392	357
Shares Outstanding (Diluted)	404	408	407	407	392	357
Shares Change	-2.46%	0.19%	-0.18%	3.93%	9.84%	-1.93%
EPS (Basic)	0.45	0.35	0.27	0.39	0.42	0.35
EPS (Diluted)	0.45	0.35	0.27	0.39	0.42	0.35
EPS Growth	79.29%	29.63%	-30.77%	-7.14%	20.00%	66.67%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	230.4	122.04	-23.36	-89.33	-84.33	24.24
Free Cash Flow Per Share	0.57	0.30	-0.06	-0.22	-0.21	0.07
Dividend Per Share	0.190	0.220	0.140	0.160	0.041	-
Dividend Growth	35.71%	57.14%	-12.50%	290.24%	-	-
Gross Margin	64.03%	63.58%	61.95%	67.40%	70.92%	74.28%
Operating Margin	22.93%	19.19%	13.37%	17.91%	19.05%	24.48%
Profit Margin	20.79%	17.98%	15.99%	25.54%	31.88%	31.72%
Free Cash Flow Margin	26.24%	15.38%	-3.40%	-14.36%	-16.33%	6.16%
EBITDA	279.65	225.7	165.73	157.42	135.68	125.2
EBITDA Margin	31.85%	28.45%	24.13%	25.30%	26.27%	31.80%
D&A For EBITDA	78.31	73.42	73.9	46	37.29	28.81
EBIT	201.35	152.28	91.83	111.42	98.39	96.4
EBIT Margin	22.93%	19.19%	13.37%	17.91%	19.05%	24.48%
Effective Tax Rate	13.79%	13.51%	7.88%	1.47%	5.19%	12.83%
Revenue as Reported	418.58	793.39	686.84	622.19	516.55	393.79
Advertising Expenses	-	1.78	2.93	4.69	8.94	2.87